Judges Scientific (JDG) Q2 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 TU earnings summary
23 Jul, 2026Executive summary
Trading in H1 2026 was significantly weaker than the prior year due to the absence of a Geotek coring expedition and uncertainties around US federal funding for scientific research, as well as delays in offshore wind projects and China's R&D tax exemption processes.
Eight businesses achieved growth, supported by internal initiatives and positive market dynamics in battery development and semiconductors.
Cost reduction actions were implemented, and progress was made at businesses facing product-specific challenges.
Financial highlights
Order intake declined 11% compared to H1 2025, with the drop concentrated in Q1; Q2 order intake was broadly in line with the prior year.
Order book stood at 17.3 weeks, compared to 15.7 weeks at FY 2025 and 17.4 weeks at H1 2025.
Revenue decreased by 21% year-over-year, with all regions declining except the UK (flat); Rest of World revenue grew 9% when adjusted for the coring expedition.
Cost base of underperforming businesses reduced by £2m in H1.
Adjusted earnings per share for H1 expected in the range of 38p–42p.
Outlook and guidance
Near-term focus is on booking shippable orders in Q3 and fulfilling the order book.
Board anticipates delivering adjusted EPS in line with current market expectations for FY2026 (202.8p).
Healthy order book and solid financial position support confidence in long-term shareholder returns and continued acquisition strategy.
2027 market expectations (231.4p adjusted EPS) do not include any Geotek coring revenue, as the next expedition is now expected no earlier than 2028.
Latest events from Judges Scientific
- Revenue up 9.1%, organic orders down 6%, dividend up 10%, 2026 EPS guided at 200–250p.JDG
H2 20251 Apr 2026 - 2025 EPS fell short and 2026 guidance is lower amid US and offshore wind market headwinds.JDG
Trading update22 Jan 2026 - H1 profits fell, but acquisitions, dividend growth, and H2 outlook improved.JDG
H1 202420 Jan 2026 - 2024 saw lower revenue and profit but strong cash flow, acquisitions, and dividend growth.JDG
H2 20241 Dec 2025 - Strong revenue and profit growth, but US market headwinds and funding cuts persist.JDG
H1 202518 Sep 2025 - FY25 EPS guidance cut due to US headwinds, but order book and cash remain strong.JDG
Trading Update24 Jul 2025 - 2024 earnings guidance lowered as delayed orders impact full-year results despite H2 progress.JDG
Trading Update13 Jun 2025 - Earnings per share for 2024 are now forecast 5–10% below consensus after a subdued H1.JDG
Trading Update13 Jun 2025 - 2024 was challenging for Judges Scientific, but 2025 starts with improved outlook and cash conversion.JDG
Trading Update6 Jun 2025